Brief: Heidelberg Pharma And Indiana University Publish Results On HER2-ATAC In Science Translational Medicine

Heidelberg Pharma AG

11/02/2021 07:01

Feb 11 (Reuters) - Heidelberg Pharma AG  HPHA.DE :
    * HEIDELBERG PHARMA AND INDIANA UNIVERSITY PUBLISH RESULTS
ON
HER2-ATAC FOR TARGETED IMMUNOTHERAPY OF TRIPLE NEGATIVE BREAST
CANCER IN SCIENCE TRANSLATIONAL MEDICINE
    * EXTRAORDINARY EFFICACY OF A HER2-TARGETING
TRASTUZUMAB-ATAC IN
TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER (TNBC) WITH LOW HER2
EXPRESSION AND HEMIZYGOUS DELETION OF CHROMOSOME 17P IN
PRECLINICAL MODELS
    * INDUCTION OF IMMUNOGENIC CELL DEATH BY AN HER2-ATAC -
SYNERGISTIC AND INCREASED EFFICACY IN COMBINATION WITH
CHECKPOINT INHIBITORS

Source text for Eikon:  ID:nEQ4WQm1Xa 
Further company coverage:  HPHA.DE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))